Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $563

Benzinga · 6d ago
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and raises the price target from $500 to $563.